La vendita allo scoperto per Health Catalyst dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Health Catalyst. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Health Catalyst (NASDAQ:HCAT) Azioni, Report sulle vendite allo scoperto

Health Catalyst

Health Catalyst Inc provides data and analytics technology and services to healthcare organizations. It has two operating segments. The Technology segment, the key revenue driver, includes data platforms, analytics applications, and support services. This generates revenues mainly from contracts that are cloud-based subscription arrangements, time-based license arrangements, and maintenance and support fees; the Professional Services segment is generally the combination of analytics, implementation, strategic advisory, outsourcing, and improvement services to deliver expertise to its customers to more fully configure and utilize the benefits of the technology offerings.

Health Catalyst Inc

<ul>
<li>Wearable robot 'X-ble Shoulder' to boost industrial efficiency and reduce musculoskeletal injuries</li>
<li>Designed to assist overhead work by enhancing upper arm muscle strength, expected to find use in various industries</li>
<li>The strong yet lightweight X-ble Shoulder enhances worker comfort by reducing shoulder load by 60% and muscle activity by 30%</li>
<li>Hyundai Motor and Kia's Robotics LAB announced commercialization plan for X-ble Shoulder, expected to begin deliveries in first half of 2025</li>
</ul>

News

HYMTF

Reported Wednesday, Hyundai And Kia To Debut 'X-ble Shoulder' In 2025, Cutting Muscle Activity And Enhancing Worker Comfort For Overhead Tasks

EVTV

Reported Wednesday, Envirotech Vehicles Delivers Electric Vans To FedEx Partners, Promising Cost Savings And Zero Emissions

Macro Economic Events

Econ #s

Economics

France Harmonised Index of Consumer Prices (MoM) Preliminary For November -0.1% Vs. 0.0% Est.; 0.3% Prior

France Gross Domestic Product (QoQ) For Q3 0.4% Vs. 0.4% Est.; 0.2% Prior

France Gross Domestic Product (YoY) For Q3 1.2% Vs. 1.3% Est.; 1.0% Prior

France Consumer Price Index (MoM) Preliminary For -0.1% Vs. 0.0% Est.; 0.2% Prior

France Consumer Spending (MoM) For September -0.4% Vs. -0.1% Est.; 0.1% Prior

Tesla Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) has introduced a major enhancement to its <a href="https://www.benzinga.com/topic/optimus">humanoid robot, Optimus</a>, featuring new hands.
What Happened: This announcement aligns with Neuralink&#8216;s recent FDA approval for its CONVOY Study. This trial will let Neuralink test its Brain-to-Computer (BCI) implant with assistive robotic arms – such as those of the Optimus bot.
This development follows Neuralink&#8217;s announcement of FDA approval for its CONVOY study, which will test the Brain-to-Computer-interface (BCI) N1 Implant with assistive robotic arms.
During a Neuralink update in July, Musk suggested that Optimus limbs could potentially work alongside the N1 implant. Neuralink also plans to allow participants to enroll in both the CONVOY and PRIME studies, the latter having already enabled two patients to control devices with their minds.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">We're excited to announce the approval and launch of a new feasibility trial to extend BCI control using the N1 Implant to an investigational assistive robotic arm. This is an important first step towards restoring not only digital freedom, but also physical freedom. More info…
&mdash; Neuralink (@neuralink) <a href="https://twitter.com/neuralink/status/1861107594645119006?ref_src=twsrc%5Etfw">November 25, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
The latest update from Tesla Optimus humorously stated, &#8220;Got&nbsp;a new hand for Black&nbsp;Friday,&#8221; showcasing the robot&#8217;s capability to catch&nbsp;a tennis ball with its&nbsp;upgraded hand.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Got a new hand for Black Friday <a href="https://t.co/x3gQrsbYAQ">pic.twitter.com/x3gQrsbYAQ</a>
&mdash; Tesla Optimus (@Tesla_Optimus) <a href="https://twitter.com/Tesla_Optimus/status/1862116407594377698?ref_src=twsrc%5Etfw">November 28, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
In May,&nbsp;CEO Elon Musk&nbsp;indicated plans to enhance Optimus&#8217; hands to achieve 22 degrees of freedom, nearing the 27 degrees found in human hands.
See Also: <a href="https://www.benzinga.com/tech/24/11/42230503/tesla-cybercab-spotted-testing-in-giga-texas-facility">Tesla Cybercab Spotted Testing In Giga Texas Facility</a>
Why It Matters: The unveiling of the new hand upgrade for Tesla&#8217;s Optimus robot comes at a time when the company is making strides in autonomous navigation and interaction capabilities.
In October, Tesla showcased Optimus&#8217; ability to autonomously navigate a factory, avoid obstacles, and <a href="https://www.benzinga.com/news/24/10/41376564/tesla-showcases-optimus-autonomous-navigation-charging-abilities-after-admitting-they-were-human-ass">interact with humans</a> by handing over snacks and drinks upon request.
Moreover, Musk&nbsp;recently <a href="https://www.benzinga.com/tech/24/11/41834327/elon-musk-reveals-toughest-part-of-building-teslas-humanoid-robot-improving-the-design-of-optimus-for-ease-of-manufacturing">acknowledged the challenges</a> in refining Optimus&#8217; design for easier manufacturing and establishing a complex supply chain for mass production. Despite these hurdles, Musk remains optimistic about the long-term economic potential of humanoid robots driven by artificial general intelligence.
In a related development, <a href="https://www.benzinga.com/24/11/42159490/elon-musks-tesla-hunts-top-talent-to-develop-software-for-robotaxi-optimus-robot-teleoperation-2">Tesla is actively seeking top talent</a> to enhance software for the teleoperation of its robotaxis and Optimus robots. This initiative aims to develop low-latency, reliable data streaming solutions for real-world applications.
Price Action: Tesla stock closed at $332.89 on Wednesday, down 1.6% for the day. In after-hours trading, the stock increased slightly by 0.5%. Year to date, Tesla's stock has gained 34%, according to&nbsp;<a href="https://pro.benzinga.com/dashboard" target="_blank" rel="noreferrer noopener">data from Benzinga Pro</a>.
Analysts have a consensus rating of "Neutral" on the Tesla stock, according to Benzinga Pro data. The highest price target is $400, while the consensus price target is 232.20, implying a 30% downside.
Check out more of Benzinga's Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/tech/24/11/42183055/elon-musk-slams-californias-proposal-to-shut-tesla-evs-out-of-consumer-rebates-in-state-this-is-insane?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Elon Musk Slams California&#8217;s Proposal To Shut Tesla EVs Out Of Consumer Rebates In State: &#8216;This Is Insane'</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: Tesla

Tech

TSLA

Tesla's Optimus Bot Gets New Hands As Neuralink's FDA-Approved BCI Trials Begin

Major U.S. indices have advanced between 18% to 27% year-to-date. The S&amp;P 500 Index scaled its 52nd record high this year on Tuesday, Nov. 26. Bulls and Bears are locking horns as S&amp;P 500 is on track to deliver 20% plus year-to-date gains for the second time.
What Happened: Markets have been under pressure only once in the month of December over the last 95 years, according to the data highlighted by Ryan Detrick, chief market strategist at Carson Group LLC.
Thanksgiving falls on the fourth Thursday of November every year, addressing the next month of December, Detrick shared the data and said &#8220;Something to be thankful for?&#8221;, in an X (formerly Twitter). The data from 1928 to 2023 showed that September has been the worst 13 times while April is the worst month this year with a 4% drop.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Something to be thankful for? December has been the worst month of the year for stocks only once going back 95 years (2018 and the Fed policy mistake). Worst month this year has been the 4% drop in April. <a href="https://t.co/2ThL3DwD7x">pic.twitter.com/2ThL3DwD7x</a>
&mdash; Ryan Detrick, CMT (@RyanDetrick) <a href="https://twitter.com/RyanDetrick/status/1862188406505185730?ref_src=twsrc%5Etfw">November 28, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Also read: <a href="http://GOP Megadonor Ken Griffin Slashes Citadel's Palantir Stake By 91%, Bets Big On Nvidia As Jensen Huang-Led Company Rises Over 180% In 2024">GOP Megadonor Ken Griffin Slashes Citadel&#8217;s Palantir Stake By 91%, Bets Big On Nvidia As Jensen Huang-Led Company Rises Over 180% In 2024</a>
On the other hand, David Cox, CMT, CFA, portfolio manager at Raymond James Ltd., in an X Post highlighted the likelihood of an upcoming to the investors, saying &#8220;If you want to sidestep a decline, watch the trend…&#8221;
The 13/34-week Exponential Moving Average signals a bullish market trend when the 13-week EMA line is above the 34-week EMA line and a bullish crossover results in a market correction. Predicting an upcoming crossover through his chart Cox said that &#8220;there will be another red circle some day&#8221;, The red circle in his chart represents a bullish crossover.
According to a <a href="https://www.cmgwealth.com/ri/how-i-think-about-the-13-34-week-exponential-moving-average/">note by CMGWealth</a>, the 13/34-week EMA analysis is a &#8220;simple, tactical trend indicator that has historically captured the cyclical bull and bear market trends.&#8221;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">again, look at how much easier we can make it on ourselves&#8230; time frame matters, if you want to sidestep a decline, watch the trend&#8230; look at these 13/34-week EMA <a href="https://twitter.com/hashtag/bearish?src=hash&amp;ref_src=twsrc%5Etfw">#bearish</a> crossovers&#8230; they help you remove emotion, and stay focused&#8230; there will be another red circle some day <a href="https://t.co/kpAXx8F5jX">pic.twitter.com/kpAXx8F5jX</a>
&mdash; David Cox, CMT, CFA (@DavidCoxRJ) <a href="https://twitter.com/DavidCoxRJ/status/1861758050215891069?ref_src=twsrc%5Etfw">November 27, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Why It Matters: Markets have been trading higher than their pre-election levels and the expectations of a further 25 basis point rate cut in December rose to just 66.3%, according to <a href="https://www.cmegroup.com/markets/interest-rates/cme-fedwatch-tool.html">CME Group&#8217;s FedWatch tool</a>. This indicates a further upside in the stock markets.
The S&amp;P 500 index has risen 26.48% year-to-date to basis. Whereas, the Nasdaq 100, Dow Jones, and Russell 200 Index have returned 25.39%, 18.58%, and 20.54%, respectively. The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) was up by 26.7% and the Invesco QQQ ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NYSE">QQQ</a>) advanced by 23.39%, according to Benzinga Pro data.
Read next: <a href="https://www.benzinga.com/general/market-summary/24/11/42206673/trumps-running-mate-vice-president-pick-and-venture-capitalist-jd-vance-holds-etfs-bitcoin-and-more-here-is-a-look-at-his-portfolio" target="_blank" rel="noreferrer noopener">JD Vance&#8217;s Investment Playbook Has Bitcoin And ETFs: Here&#8217;s What Else The VP-Elect Is Betting On</a>

Equities

Markets

Wall Street's December Surprise: What Investors Need to Know Now

BIIB

ESAIY

Reported Wednesday, Eisai and Biogen Introduce LEQEMBI In South Korea To Combat Alzheimer's And Mild Cognitive Impairment

Reported Wednesday, KKR And Weave Living Strengthen Partnership With $3,000+ Unit Residential Program In Japan

ZLAB

Reported Wednesday, Zai Lab Announces AUGTYRO Inclusion For ROS1+ NSCLC In China's Updated National Reimbursement Drug List

This collaboration aims to provide scalable solutions, accelerate time-to-market, and deliver innovative advancements. It will leverage Tech Mahindra's specialized talent pool and advanced labs, focusing on technologies expected to drive the future of connected devices, additive manufacturing, connected vehicles, and augmented and virtual reality. The center marks a significant milestone for USI as it expands its engineering capabilities to India, providing a strong foundation for enhancing device software development, hardware design, and testing. USI aims to&nbsp;leverage&nbsp;Tech Mahindra's expertise, particularly the need for scalability and flexibility, faster product launches, and access to specialized skills and facilities.&nbsp;

Reported Thursday, ASE Technology Subsidiary USI Partners With Tech Mahindra To Establish Engineering Offshore Development Center In Bengaluru

ORPATHYS&#xAE;&nbsp;is an oral, potent, and highly selective MET tyrosine kinase inhibitor ("TKI"). It received conditional approval in China in June 2021 for the treatment of certain patients with non-small cell lung cancer ("NSCLC") with MET exon 14 skipping alterations. More than a third of the world's lung cancer patients are in China and, among those with NSCLC globally, approximately 2-3% have tumors with MET exon 14 skipping alterations.

Reported Thursday, HUTCHMED Confirms ORPATHYS (Savolitinib) Retains Spot On China's National Reimbursement Drug List

<ul>
<li>New Barcelona site to help drive global expansion of QIAstat-Dx as QIAGEN expands local presence with multi-year investment</li>
<li>Site in Esplugues de Llobregat to serve as an innovation hub for QIAstat-Dx, supporting the development of infectious disease tests and precision medicine applications</li>
</ul>

QGEN

Reported Thursday, QIAGEN Boosts QIAstat-Dx With New Barcelona Hub For Infectious Disease And Precision Medicine Testing

<ul>
<li>Only immuno-oncology drug approved by various regulatory authorities around the world such as the USFDA, DCGI, EMA, MHRA, NMPA and others for the treatment of adults with recurrent or metastatic nasopharyngeal carcinoma (RM-NPC)</li>
<li>Combination of Toripalimab and standard of care chemotherapy has shown a 48% reduction in risk of progression or death</li>
<li>Launched in India in the same year as its launch in the U.S., making India the third country in the world to receive access to this New Biological Entity (NBE)</li>
</ul>

Reported Thursday, Dr. Reddy's Introduces Toripalimab In India, Immuno-Oncology Drug Approved For The Treatment Of Nasopharyngeal Carcinoma

Management

MATH

Reported Thursday, Metalpha Technology Appoints Pengyuan Fan As Chief Financial Officer, Effective November 28

Germany Retail Sales (MoM) For October -1.5% Vs. -0.5% Est.; 1.2% Prior

Mixed martial arts legend Khabib Nurmagomedov has thrown his support behind a &#8216;satirical&#8217; meme coin that is raising funds to help the victims of Conor McGregor, a fellow Ultimate Fighting Championship (UFC) fighter found guilty of sexual assault.
What Happened: In an X post on Thursday, Nurmagomedov praised the so-called CONVICT project for taking up the initiative.
&#8220;Good job guys , you have my full support, this guy deserves punishment,&#8221; the UFC Hall of Famer said.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Good job guys , you have my full support, this guy deserve punishment <a href="https://t.co/tOFNJrBUYV">https://t.co/tOFNJrBUYV</a>
&mdash; khabib nurmagomedov (@TeamKhabib) <a href="https://twitter.com/TeamKhabib/status/1861871405341581729?ref_src=twsrc%5Etfw">November 27, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
CONVICT describes itself as a &#8220;satirical meme coin&#8221; influenced by McGregor&#8217;s recent conviction in the sexual assault civil case. It has called for donations to its cryptocurrency address to cover the legal fees of McGregor&#8217;s victims.
The coin, which trades on Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>)-based decentralized exchange (DEX)&nbsp;Raydium, saw its market valuation jump to $336,370, per <a href="https://coinmarketcap.com/dexscan/solana/9wRdTaGGDct1HH4oTfGAxyU8nEo4H4rzYcdzvso8QCgd/">CoinMarketCap</a>.
Note that the coin has very low liquidity, about $82,900, as of this writing, making it vulnerable to wild price swings. Additionally, its absence from mainstream cryptocurrency exchanges raises another red flag.
A civil court jury found last week that McGregor <a href="https://edition.cnn.com/2024/11/26/sport/conor-mcgregor-civil-rape-verdict-spt-intl/index.html">assaulted </a>a woman in a Dublin hotel in December 2018, ordering him to pay her nearly €250,000, roughly $263,600, in damages, per a CNN report.
The Irish MMA fighter&#8217;s reputation has since taken a big hit, with his wax figure getting removed from the National Wax Museum Plus in Dublin, the BBC <a href="https://www.bbc.com/news/articles/c0j8xq3zdn5o">reported</a>. 
See Also:&nbsp;<a href="https://www.benzinga.com/24/11/42238227/trader-turns-160-into-6m-in-just-12-days-with-chill-guy-meme-coin-but-concerns-of-insider-trading-arise">Trader Turns $160 Into $6M In Just 12 Days With &#8216;Chill Guy&#8217; Meme Coin But Insider Trader Concerns Arise</a>
Why It Matters: Interestingly, this isn&#8217;t the first time Nurmagomedov has been linked to controversial cryptocurrency ventures. 
Last year the MMA legend <a href="https://www.benzinga.com/markets/cryptocurrency/23/02/31111704/coffeezilla-picks-nft-fight-with-mma-legend-khabib-nurmagomedov-scamming-your-fans">faced accusations</a> from &#8220;Crypto Detective&#8221; Coffeezilla for promoting a potential cryptocurrency scam involving his new non-fungible token (NFT) project. 
Nurmagomedov launched an exclusive NFT collection in partnership with GoMining, a cryptocurrency mining platform, promising fans access to his "private club" and the ability to mine Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>).
Photo Courtesy: Camerasandcoffee On Shutterstock.com
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/24/11/42237876/peter-schiff-predicts-microstrategys-bankruptcy-due-to-bitcoin-investment-strategy">Peter Schiff Calls MicroStrategy A &#8216;Great Short&#8217; And Issues A Grim Warning: &#8216;It Can Only End In Bankruptcy&#8217;</a></li>
</ul>

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$SOL

MMA Star Khabib Nurmagomedov Backs Meme Coin 'Fighting' For Conor McGregor's Victims: 'This Guy Deserves Punishment'

Lvmh Moet Hennessy Louis's (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LVMHF#OTC">LVMHF</a>) Bernard Arnault has denied knowledge of any alleged spying and intelligence peddling.
What Happened: Arnault, the chief of LVMH, testified in a high-stakes trial on Thursday, denying any knowledge of an alleged scheme to protect the luxury group, <a href="https://fortune.com/europe/2024/11/28/billionaire-bernard-arnault-court-completely-unaware-ex-spy-chief-abused-powers-protect-lvmh/">reported</a> Fortune.
France&#8217;s wealthiest man was called to testify in the trial of Bernard Squarcini, the former head of France&#8217;s domestic intelligence agency.
Squarcini is one of ten men on trial, facing charges of using his security contacts for private gain, including obtaining confidential information on behalf of LVMH.
See Also: <a href="https://www.benzinga.com/24/11/42228090/bitcoin-ethereum-dogecoin-surge-as-traders-raise-risk-appetite-ahead-of-thanksgiving-analyst-says-eth-could-jump-to-highs-not-seen-since-late-2021?itm_source=parsely-api">Bitcoin, Ethereum, Dogecoin Surge As Traders Raise Risk Appetite Ahead Of Thanksgiving: Analyst Sets Mid-Term Price Target For ETH At $6K</a>
The charges against Squarcini relate to his tenure as the head of the DCRI security service from 2008-2012 and his subsequent return to the private sector, where he largely worked for LVMH as a consultant.
Investigators state that DCRI officers were deployed as early as 2008 to identify a blackmailer targeting Arnault.
Arnault stated in court, &#8220;I was completely unaware&#8221; of the alleged scheme.&nbsp;
He also denied any knowledge of an attempted blackmail targeting his private life in 2008, for which the DCRI mobilized its agents to identify the blackmailer, the report noted.
The LVMH boss also refuted allegations related to spying on Francois Ruffin, a former journalist and current left-wing lawmaker, and the leftist newspaper Fakir that Ruffin founded.
LVMH had previously settled out of court in 2021, paying 10 million euros in fines, but Arnault and LVMH were never put on trial.
Why It Matters: This trial comes at a challenging time for LVMH, which has been grappling with a decline in revenue. The company&#8217;s third-quarter revenue fell by 3%, falling short of analyst forecasts.
The French luxury empire led by Arnault boasts an impressive portfolio of premium jewelry, fashion, and spirits brands. Many of its offerings, particularly those under the iconic Louis Vuitton label, are priced at over $1,000.
This latest downturn has been attributed to sluggish demand from shoppers throughout the year. The trial could potentially add to the company&#8217;s woes, depending on the outcome.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/11/42225423/mexico-president-claudia-sheinbaum-to-trump-neither-threats-nor-tariffs-will-solve-your-fentanyl-crisis?itm_source=parsely-api">Mexico President Claudia Sheinbaum To Trump: &#8216;Neither Threats Nor Tariffs&#8217; Will Solve Your Fentanyl Crisis</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Legal

Media

LVMHF

LVMH CEO Bernard Arnault Denies Spying Allegations And Influence-Peddling Ties During Legal Testimony

Sees FY24 adjusted EBITDA between $25.0 million and $27.0 million. Published first on TheFly – the ultimate source for real-time, market-moving bre...

Health Catalyst sees FY24 revenue $305M- $311M, consensus $307.49M

Health Catalyst (HCAT) announced a new partnership with CyncHealth, the designated statewide health information exchange for Iowa. This partnership...

Health Catalyst announces partnership with CyncHealth

Health Catalyst Non-GAAP EPS of $0.07 misses by $0.02, revenue of $76.4M in-line

Health Catalyst, Inc. (HCAT) Q3 2024 Earnings Call Transcript

In a report released today, Stephanie Davis from Barclays maintained a Buy rating on Health Catalyst (HCAT – Research Report), with a price target ...

Barclays Sticks to Their Buy Rating for Health Catalyst (HCAT)

Analyst David Larsen of BTIG maintained a Buy rating on Health Catalyst (HCAT – Research Report), retaining the price target of $13.00. David Larse...

Health Catalyst Poised for Growth: Strong Q3 Performance and Strategic Positioning Drive Buy Rating

Health Catalyst ( ($HCAT) ) has released its Q3 earnings. Here is a breakdown of the information Health Catalyst presented to its investors. Health...

Health Catalyst Reports Q3 Revenue Growth Amid Reduced Losses

Stephens analyst Jeff Garro raised the firm's price target on Health Catalyst (HCAT) to $9 from $7 and keeps an Equal Weight rating on the shares f...

Health Catalyst price target raised to $9 from $7 at Stephens

In a report released yesterday, Anne Samuel from J.P. Morgan maintained a Buy rating on Health Catalyst (HCAT – Research Report), with a price targ...

Health Catalyst (HCAT) Receives a Buy from J.P. Morgan

Piper Sandler raised the firm's price target on Health Catalyst (HCAT) to $12 from $11 and keeps an Overweight rating on the shares after updating ...

Comments

Health Catalyst

Vendite allo scoperto

Health Catalyst (NASDAQ:HCAT) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO